GLYSCEND
Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathwa... ys in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
GLYSCEND
Industry:
Biopharma Biotechnology Cosmetic Surgery Landscaping Medical Pharmaceutical Therapeutics
Founded:
2014-01-01
Address:
Baltimore, Maryland, United States
Country:
United States
Website Url:
http://www.glyscend.com
Total Employee:
1+
Status:
Active
Total Funding:
22.42 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins
Current Advisors List
Board_member
2020-06-11
Board_member
2020-06-11
Board_member
2020-06-11
Board_member
2019-09-01
Current Employees Featured
Ashish Nimgaonkar Founder, President, CEO & Board Member @ Glyscend
Founder, President, CEO & Board Member
2016-06-01
Pankaj Pasricha Co Founder @ Glyscend
Co Founder
2014-01-01
Founder
Investors List
Medical Research Commercialisation Fund (MRCF)
Medical Research Commercialisation Fund (MRCF) investment in Series A - Glyscend
Sante Ventures
Sante Ventures investment in Series A - Glyscend
Breakout Labs
Breakout Labs investment in Seed Round - Glyscend
National Science Foundation
National Science Foundation investment in Grant - Glyscend
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Grant - Glyscend
NSF Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR)
NSF Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR) investment in Grant - Glyscend
Official Site Inspections
http://www.glyscend.com
- Host name: wp5.bluehost.com
- IP address: 162.241.16.11
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Glyscend"
About Us - Glyscend
Glyscend Therapeutics is a venture-backed, clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity.See details»
Glyscend Therapeutics - Crunchbase Company Profile …
Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia.See details»
Glyscend Therapeutics - LinkedIn
The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive …See details»
Glyscend Therapeutics Company Profile 2024: Valuation, Funding ...
Glyscend Therapeutics is headquartered in Baltimore, MD. What is the size of Glyscend Therapeutics? Glyscend Therapeutics has 16 total employees. What industry is Glyscend …See details»
glyscend Company Profile - Office Locations, Competitors, …
Glyscend is a company that develops a method of treating metabolic diseases. It aims to provide a non-invasive approach for treating type two diabetes allowing control glucose level and such …See details»
Science - Glyscend
Glyscend’s lead product candidate, GLY-200, is the first and only clinical-stage, potentially disease-modifying, pharmacologic polymer therapy for T2D and obesity. This orally-administered therapy is being developed to modulate the …See details»
Pharmacologic duodenal exclusion: a novel therapy for …
Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is ...See details»
Glyscend Doses First Patient in a Phase 2 Obesity Trial …
BOSTON, June 03, 2024--Glyscend Therapeutics, a clinical-stage biopharmaceutical company advancing first-in-class oral polymeric drugs for the treatment of metabolic disease, today announced the ...See details»
Glyscend Therapeutics Announces Positive Topline …
May 31, 2023 Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing novel, orally administered, polymer therapies that work on targets inside the gastrointestinal tract to treat a ...See details»
Glyscend Therapeutics Announces Publication of GLY-200 First-in …
Jul 27, 2023 Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing novel, orally administered, polymer therapies that work on targets inside the gastrointestinal …See details»
Glyscend Therapeutics Announces Completion of Phase 1 Clinical …
May 11, 2022 Glyscend Therapeutics is a venture-backed, clinical-stage biopharmaceutical company developing novel orally administered, polymer therapies that work on targets inside …See details»
News - Glyscend
B oston, MA (June 3, 2024) – Glyscend Therapeutics… today announced the initiation of a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity. GLY-200 …See details»
Glyscend pioneering new class of GI-targeted therapy for T2D and ...
Sep 5, 2023 Glyscend is planning a longer-duration Phase 2b clinical trial in about 200 obese Type 2 diabetes patients and 200 obese patients without Type 2 diabetes. The study is …See details»
Glyscend’s First-in-Class Oral Diabetes Drug Shows Phase
May 31, 2023 Glyscend will present these Phase I data and pre-clinical results at the upcoming American Diabetes Association 83rd Scientific Sessions. GLY-200’s first-in-class potential …See details»
Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, …
Jun 3, 2024 Glyscend Therapeutics is a clinical-stage biopharmaceutical company that is taking a novel approach to the treatment of metabolic disease, led by obesity and type 2 diabetes …See details»
Glyscend Therapeutics commences South Australia Phase I clinical …
Aug 3, 2021 Glyscend’s technology could enable, not just the treatment but potentially a reversal of T2D. Glyscend’s novel synthetic polymers are inert, non-absorbed, and naturally eliminated …See details»
Glyscend Therapeutics Announces Initiation of Phase 1 Clinical …
Sep 28, 2021 Glyscend Therapeutics is a venture-backed biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a …See details»
Glyscend’s first-in-class oral diabetes drug shows Phase II promise
May 31, 2023 Glyscend will present these Phase I data and pre-clinical results at the upcoming American Diabetes Association 83rd Scientific Sessions. GLY-200’s first-in-class potential …See details»
Clinical Trials - Glyscend
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants with ObesitySee details»